Legato Capital Management LLC Takes Position in Roivant Sciences Ltd. $ROIV

Legato Capital Management LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 32,205 shares of the company’s stock, valued at approximately $487,000.

Other hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its holdings in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares during the period. Bessemer Group Inc. lifted its position in Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. CWM LLC boosted its stake in Roivant Sciences by 44.6% during the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the period. Osaic Holdings Inc. grew its position in Roivant Sciences by 204.2% in the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock worth $65,000 after purchasing an additional 3,882 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd increased its stake in shares of Roivant Sciences by 75.8% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after purchasing an additional 1,900 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Roivant Sciences

In other news, insider Frank Torti sold 587,390 shares of Roivant Sciences stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the transaction, the insider owned 13,736,547 shares of the company’s stock, valued at $377,892,407.97. The trade was a 4.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the sale, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at approximately $43,830,274.53. This represents a 10.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,318,014 shares of company stock valued at $315,727,023 over the last 90 days. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the topic of a number of recent analyst reports. HC Wainwright lifted their price target on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Wednesday. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, February 9th. Guggenheim increased their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $28.81.

Roivant Sciences Stock Up 6.0%

Shares of Roivant Sciences stock opened at $29.52 on Thursday. The business has a fifty day simple moving average of $24.28 and a 200-day simple moving average of $19.85. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $29.83. The firm has a market cap of $21.13 billion, a price-to-earnings ratio of -25.23 and a beta of 1.17.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant (via subsidiary Genevant) and Arbutus announced a $2.25 billion global settlement with Moderna that includes a $950M upfront payment and up to $1.3B contingent on a favorable appeal — a major cash and litigation-risk removal for Roivant’s LNP business. Read More.
• Positive Sentiment: The board approved an expanded $1 billion share repurchase program (inclusive of a prior $500M authorization), which supports buyback-driven EPS/reduced share float dynamics and likely contributed to the rally. Read More.
• Positive Sentiment: Priovant (a Roivant affiliate) received FDA acceptance and Priority Review for brepocitinib in dermatomyositis with a PDUFA date in Q3 2026 — approval would create a first-in-class targeted therapy and potential commercial upside. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $34 and maintained a Buy rating, providing analyst support and signaling ~15% upside from current levels. Read More.
• Neutral Sentiment: The $1.3B additional payment is contingent on a favorable resolution of Moderna’s Section 1498 appeal — meaningful upside but dependent on litigation outcome and timing, introducing uncertainty to the total cash Roivant ultimately receives. Read More.
• Negative Sentiment: Pfizer/BioNTech litigation remains ongoing in the U.S.; while the Moderna settlement materially de-risks one front, continued legal exposure and appeals across the sector leave some patent and revenue uncertainty. Read More.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.